A
Class-leading
Injectable division · GLP-1/GIP/glucagon triple
Retatrutide
Eli Lilly · once weekly
Certified: Phase 3 toplinenot yet approved
Division standing
#1 of 5
the injectable frontier
← Tolerability cost (bands)% body weight lost →
Notable021% vs placebo *
Tolerability: the cost
Notable11.3% vs 4.9% placebo
AE-discontinuation +6.4 points, at the 12 mg weekly. From TRIUMPH-1.
Efficacy: the frontier
21%12 mg · placebo-adjusted · 80 wk *
TRIUMPH-1: 25% vs 3.9% placebo, a 21-point gap on the treatment-regimen estimand. The efficacy estimand runs 26.1 points. Read at 80 weeks, past the standard window, flagged and not extrapolated. * Topline, not yet peer-reviewed.
The honest tension: it melts the most fat, and it is among the hardest to stay on. Shown as two arms, never averaged into one.
The 21-point figure is the treatment-regimen estimand inferred from topline (about 25.0% vs 3.9% placebo); only the efficacy-estimand pair (28.3% vs 2.2%) is disclosed in full, and TRIUMPH-1 is topline plus ADA, not yet peer-reviewed.
Read at 80 weeks, outside the 68 to 72 week standard window, so it is used and marked rather than compared head-on.
Convenience profile: you weigh it, not us
Route
Subcutaneous injection
Frequency
Once weekly
Food / water rule
None
Titration
Long multi-step escalation over several months
Storage
Refrigerated
Provenance: every number traces back
TrialTRIUMPH-1 · NCT05929066
Estimandtreatment-regimen estimand (efficacy estimand labeled)
Populationnon-diabetic obesity
Dose12 mg weekly
SourceLilly press release, 21 May 2026; ADA 2026 presentation, 6 Jun 2026
Verdict confirmed8 Jul 2026
Next milestone: TRIUMPH-1 peer-reviewed publication and first regulatory submissionMechanism field guide →